Safety of Japanese encephalitis vaccines

References

• Mansfield KL, Hernández-Triana LM, Banyard AC, Fooks AR, Johnson N. Japanese encephalitis virus infection, diagnosis and control in domestic animals. Vet Microbiol. 2017;201:85–92. doi:10.1016/j.vetmic.2017.01.014.
   PubMed Web of Science ®Google Scholar
• Solomon T. Control of Japanese encephalitis–within our grasp? N Engl J Med. 2006;355:869–71. doi:10.1056/NEJMp058263.
   PubMed Web of Science ®Google Scholar
• Filgueira FL. Review of emerging Japanese encephalitis virus: new aspects and concepts about entry into the brain and inter-cellular spreading. Pathogens. 2019;8(3):111. doi:10.3390/pathogens8030111.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li M, Wang H, Liang G. Japanese encephalitis and Japanese encephalitis virus in mainland China. Rev Med Virol. 2012;22:301–22. doi:10.1002/rmv.1710.
   PubMed Web of Science ®Google Scholar
• Dung NM, Turtle L, Chong WK, Mai NT, Thao TT, Thuy TT, Kneen R, Phu NH, Wills B, Farrar J, et al. An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis. J Neurol. 2009;256:2052–60. doi:10.1007/s00415-009-5249-5.
   PubMed Web of Science ®Google Scholar
• Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol. 2002;267:171–94.
   PubMed Web of Science ®Google Scholar
• Xiong W, Lu L, Xiao Y, Li J, Zhou D. Mortality and disability due to Japanese encephalitis in elderly adults: evidence from an adult tertiary care center in West China. Frontiers in Neurology. 2019;10:918. doi:10.3389/fneur.2019.00918.
   PubMed Web of Science ®Google Scholar
• Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89:766–74, 74a-74e. doi:10.2471/BLT.10.085233.
   PubMed Web of Science ®Google Scholar
• Lee DW, Choe YJ, Kim JH, Song KM, Cho H, Bae GR, Lee JK. Epidemiology of Japanese encephalitis in South Korea, 2007-2010. Int J Infect Dis. 2012;16:e448–52. doi:10.1016/j.ijid.2012.02.006.
   PubMed Web of Science ®Google Scholar
• Choe YJ, Taurel AF, Nealon J, Seo HS, Kim HS. Systematic review of seroepidemiological studies on Japanese encephalitis in the Republic of Korea. Int J Infect Dis. 2018;67:14–19. doi:10.1016/j.ijid.2017.11.023.
   PubMed Web of Science ®Google Scholar
• Chang YK, Chang HL, Wu HS, Chen KT. Epidemiological features of Japanese encephalitis in Taiwan from 2000 to 2014. Am J Trop Med Hyg. 2017;96:382–88. doi:10.4269/ajtmh.16-0330.
   PubMed Web of Science ®Google Scholar
• Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, Lin IF, Chang FY. The incidence of Japanese encephalitis in Taiwan–a population-based study. PLoS Negl Trop Dis. 2014;8:e3030. doi:10.1371/journal.pntd.0003030.
   PubMed Web of Science ®Google Scholar
• Ma SP, Yoshida Y, Makino Y, Tadano M, Ono T, Ogawa M. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg. 2003;69:151–54. doi:10.4269/ajtmh.2003.69.151.
   PubMed Web of Science ®Google Scholar
• Pan XL, Liu H, Wang HY, Fu SH, Liu HZ, Zhang HL, Li MH, Gao XY, Wang JL, Sun XH, et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol. 2011;85:9847–53. doi:10.1128/JVI.00825-11.
   PubMed Web of Science ®Google Scholar
• Nitatpattana N, Dubot-Pérès A, Gouilh MA, Souris M, Barbazan P, Yoksan S, De Lamballerie X, Gonzalez JP. Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis. 2008;14:1762–65. doi:10.3201/eid1411.080542.
   PubMed Web of Science ®Google Scholar
• Nga PT, Parquet MDC, Cuong VD, Ma SP, Hasebe F, Inoue S, Makino Y, Takagi M, Nam VS, Morita K. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. J Gen Virol. 2004;85:1625–31. doi:10.1099/vir.0.79797-0.
   PubMed Web of Science ®Google Scholar
• Pyke AT, Williams DT, Nisbet DJ, van den Hurk AF, Taylor CT, Johansen CA, Macdonald J, Hall RA, Simmons RJ, Mason RJ, et al. The appearance of a second genotype of Japanese encephalitis virus in the Australasian region. Am J Trop Med Hyg. 2001;65:747–53. doi:10.4269/ajtmh.2001.65.747.
   PubMed Web of Science ®Google Scholar
• Lee PI, Huang YC, Hwang KP, Liu CC, Chiu CH, Chen PY, Lu CY, Chen CJ, Chang LY, Chiu NC, et al. Recommendations for the use of Japanese encephalitis vaccines. Pediatr Neonatol. 2020;61:3–8. doi:10.1016/j.pedneo.2019.11.009.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Japanese encephalitis vaccines: WHO position paper – February 2015. Wkly Epidemiol Rec 2015;90:69–87.
   PubMedGoogle Scholar
• Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis. 2013;56:267–70. doi:10.1093/cid/cis883.
   PubMed Web of Science ®Google Scholar
• Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett ADT. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004;22:3722–26. doi:10.1016/j.vaccine.2004.03.027.
   PubMed Web of Science ®Google Scholar
• Li X, Ma SJ, Liu X, Jiang LN, Zhou JH, Xiong YQ, Ding H, Chen Q. Immunogenicity and safety of currently available Japanese encephalitis vaccine: a systemic review. Hum Vaccin Immunother. 2014;10:3579–93. doi:10.4161/21645515.2014.980197.
   PubMed Web of Science ®Google Scholar
• Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother. 2014;10:263–79. doi:10.4161/hv.26902.
   PubMed Web of Science ®Google Scholar
• Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319:608–14. doi:10.1056/NEJM198809083191004.
   PubMed Web of Science ®Google Scholar
• Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian J Trop Med Public Health. 1995;26:689–93.
   PubMedGoogle Scholar
• Kurane I, Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine. 2000;18(Suppl 2):33–35. doi:10.1016/S0264-410X(00)00041-4.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011;10:355–64. doi:10.1586/erv.11.7.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine. 2000;18:2963–69.
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Staples JE, Jones JF, Sejvar JJ, Griggs A, Iskander J, Miller ER, Fischer M. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009. Vaccine. 2010;29:58–64. doi:10.1016/j.vaccine.2010.10.016.
   PubMed Web of Science ®Google Scholar
• Plesner AM, Arlien-Søborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet. 1996;348:202–03. doi:10.1016/S0140-6736(05)66156-9.
   PubMed Web of Science ®Google Scholar
• Ohtaki E, Murakami Y, Komori H, Yamashita Y, Matsuishi T. Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination. Pediatr Neurol. 1992;8:137–39. doi:10.1016/0887-8994(92)90036-X.
   PubMed Web of Science ®Google Scholar
• Ohtaki E, Matsuishi T, Hirano Y, Maekawa K. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J Neurol Neurosurg Psychiatry. 1995;59:316–17. doi:10.1136/jnnp.59.3.316.
   PubMed Web of Science ®Google Scholar
• Plesner AM, Arlien-Soborg P, Herning M. Neurological complications to vaccination against Japanese encephalitis. Eur J Neurol. 1998;5:479–85. doi:10.1046/j.1468-1331.1998.550479.x.
   PubMed Web of Science ®Google Scholar
• Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–27.
   PubMedGoogle Scholar
• Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine. 2010;28:3635–41. doi:10.1016/j.vaccine.2010.02.105.
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Meghani A, Halstead SB, Yaich M. Use of the live attenuated Japanese Encephalitis vaccine SA14-14-2 in children: a review of safety and tolerability studies. Hum Vaccin Immunother. 2017;13:2222–31. doi:10.1080/21645515.2017.1356496.
   PubMed Web of Science ®Google Scholar
• Gao X, Li X, Li M, Fu S, Wang H, Lu Z, Cao Y, He Y, Zhu W, Zhang T, et al. Vaccine strategies for the control and prevention of Japanese encephalitis in Mainland China, 1951-2011. PLoS Negl Trop Dis. 2014;8:e3015. doi:10.1371/journal.pntd.0003015.
   PubMed Web of Science ®Google Scholar
• Upreti SR, Janusz KB, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, Shrestha MM, Sedai TR, Fischer M, Gibbons RV, et al. Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA14-14-2 vaccine in Nepal. Am J Trop Med Hyg. 2013;88:464–68. doi:10.4269/ajtmh.12-0196.
   PubMed Web of Science ®Google Scholar
• Upreti SR, Lindsey NP, Bohara R, Choudhary GR, Shakya S, Gautam M, Giri JN, Fischer M, Hills SL. Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA14-14-2 vaccine in Nepal. PLoS Negl Trop Dis. 2017;11:e0005866. doi:10.1371/journal.pntd.0005866.
   PubMed Web of Science ®Google Scholar
• Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet. 2005;366:1375–78. doi:10.1016/S0140-6736(05)67567-8.
   PubMed Web of Science ®Google Scholar
• Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB. Efficacy of single-dose SA14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet. 2001;358:791–95. doi:10.1016/S0140-6736(01)05967-0.
   PubMed Web of Science ®Google Scholar
• Khan SA, Kakati S, Dutta P, Chowdhury P, Borah J, Topno R, Jadhav SM, Mohapatra PK, Mahanta J, Gupte MD. Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA14-14-2 in adults. Indian J Med Res. 2016;144:886–92. doi:10.4103/ijmr.IJMR_712_15.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC, Xiang CF, Bilker WB, Pan XP, Yao YJ, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis. 1997;176:1366–69. doi:10.1086/517323.
   PubMed Web of Science ®Google Scholar
• Wijesinghe PR, Abeysinghe MRN, Yoksan S, Yao Y, Zhou B, Zhang L, Fleming JA, Marfin AA, Victor JC. Immunogenicity of live attenuated Japanese encephalitis SA14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine. Vaccine. 2016;34:5923–28. doi:10.1016/j.vaccine.2016.10.028.
   PubMed Web of Science ®Google Scholar
• Wang Y, Dong D, Cheng G, Zuo S, Liu D, Du X. Post-marketing surveillance of live-attenuated Japanese encephalitis vaccine safety in China. Vaccine. 2014;32:5875–79. doi:10.1016/j.vaccine.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin H, Zhu Q, Wu C, Zhao Z, Zheng H. Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012. Vaccine. 2014;32:1768–73. doi:10.1016/j.vaccine.2013.11.107.
   PubMed Web of Science ®Google Scholar
• Sanchayan K, Fernandopulle R, Amarasinghe A, Thiyahiny SN, Sri Ranganathan S. Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka. Ceylon Med J. 2016;61:99–105. doi:10.4038/cmj.v61i3.8344.
   PubMed Web of Science ®Google Scholar
• Jelinek T. Ixiaro: a new vaccine against Japanese encephalitis. Expert Rev Vaccines. 2009;8:1501–11. doi:10.1586/erv.09.112.
   PubMed Web of Science ®Google Scholar
• Butler S, Sutter D, Maranich A. Tolerability of Japanese encephalitis vaccine in pediatric patients. J Pediatric Infect Dis Soc. 2017;6:149–52.
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO, Yoo WD, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine. 2001;19:4557–65. doi:10.1016/S0264-410X(01)00208-0.
   PubMed Web of Science ®Google Scholar
• Yun KW, Lee HJ, Park JY, Cho HK, Kim YJ, Kim KH, Kim NH, Hong YJ, Kim DH, Kim HM, et al. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. Vaccine. 2018;36:1398–404.
   PubMed Web of Science ®Google Scholar
• Walker WL, Hills SL, Miller ER, Fischer M, Rabe IB. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016. Vaccine. 2018;36:4369–74.
   PubMed Web of Science ®Google Scholar
• Chanthavanich P, Limkittikul K, Sirivichayakul C, Chokejindachai W, Hattasingh W, Pengsaa K, Surangsrirat S, Srisuwannaporn T, Kaewma B, Yoksan S, et al. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. Hum Vaccin Immunother. 2018;14:900–05. doi:10.1080/21645515.2017.1414763.
   PubMed Web of Science ®Google Scholar
• Wang SY, Cheng XH, Li JX, Li XY, Zhu FC, Liu P. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: a systematic review and meta-analysis. Hum Vaccin Immunother. 2015;11:1418–25. doi:10.1080/21645515.2015.1011996.
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632–49. doi:10.1016/j.vaccine.2009.09.098.
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Vrati S. Clinical development of IMOJEV ®–a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther. 2012;12:1251–63. doi:10.1517/14712598.2012.704908.
   PubMed Web of Science ®Google Scholar
• Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14–14–2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2000;62:480–84. doi:10.4269/ajtmh.2000.62.480.
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine. 2010;28:7993–8000. doi:10.1016/j.vaccine.2010.09.035.
   PubMed Web of Science ®Google Scholar
• Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, Kim HM, Kim JH, Kang JH, Kim JH, et al. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. Hum Vaccin Immunother. 2014;10:2656–63. doi:10.4161/hv.29743.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, Chokephaibulkit K, Boaz M, Meric C, Hutagalung Y, Bouckenooghe A. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Pediatr Infect Dis J. 2014;33:643–49. doi:10.1097/INF.0000000000000276.
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Pruekprasert P, Puthanakit T, Pancharoen C, Tangsathapornpong A, Oberdorfer P, Kosalaraksa P, Prommalikit O, Tangkittithaworn S, Kerdpanich P, et al. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Vaccine. 2017;35:299–304. doi:10.1016/j.vaccine.2016.11.062.
   PubMed Web of Science ®Google Scholar
• Ma HY, Lai CC, Chiu NC, Lee PI. Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017-18. Vaccine. 2020;38:5219–22. doi:10.1016/j.vaccine.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Vu TD, Nguyen QD, Tran HTA, Bosch-Castells V, Zocchetti C, Houillon G. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: a single-arm, single-center study. Int J Infect Dis. 2018;66:137–42.
   PubMed Web of Science ®Google Scholar
• Kim DS, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, et al. Immunogenicity and safety of a booster dose of a live attenuated Japanese encephalitis chimeric vaccine given 1 year after primary immunization in healthy children in the Republic of Korea. Pediatr Infect Dis J. 2016;35:e60–4.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Capeding MR, Boaz M, Gailhardou S, Meric C, Bouckenooghe A. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother. 2013;9:889–97. doi:10.4161/hv.23087.
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, Gailhardou S, Boaz M, Feroldi E. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010;29:1111–17. doi:10.1097/INF.0b013e3181f68e9c.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother. 2012;8:929–37. doi:10.4161/hv.20071.
   PubMed Web of Science ®Google Scholar
• Kim HS, Oh Y, Korejwo J, Castells VB, Yang K. Post-marketing surveillance of adverse events following vaccination with the live-attenuated Japanese encephalitis chimeric virus vaccine (Imojev(®)) in South Korea, 2015-2019. Infect Dis Ther. 2020;9:589–98. doi:10.1007/s40121-020-00305-6.
   PubMed Web of Science ®Google Scholar